The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I dose escalation study of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis.
Bruno Sangro
No relevant relationships to disclose
Todd S. Crocenzi
No relevant relationships to disclose
Theodore Hobart Welling
No relevant relationships to disclose
Mercedes Iñarrairaegui
No relevant relationships to disclose
Jesús Prieto
No relevant relationships to disclose
Carmen Fuertes
No relevant relationships to disclose
Laurie Delanty
No relevant relationships to disclose
William Feely
Employment or Leadership Position - Bristol-Myers Squibb
Jeffrey Anderson
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Dennis M. Grasela
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Jon M. Wigginton
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ashok Kumar Gupta
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Ignacio Melero
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb